COVID Collaborations: Two Ways To Define Success
In the short term, public-private partnerships engaged in the coronavirus response will be judged on whether there are effective treatments for COVID-19. But the long-term impact may be as a test of whether collaborative models can work when the stakes are high.
You may also be interested in...
FDA’s Peter Marks and Janet Woodcock will be on the bridge for Operation Warp Speed; Moncef Slaoui says early clinical data on one vaccine candidate makes him confident that a few hundred million doses of a vaccine can be available by the end of the year.
NIH public-private partnership with FDA, CDC, BARDA and 16 biopharma companies to rank most promising therapeutics and vaccines to advance into clinical trials; candidates expected to be tested simultaneously under master protocol.
Companies are racing to co-develop coronavirus treatments before finalizing deal teams. These team-ups raise questions about what happens after the pandemic subsides.